Investors flock to Chinese herbal medicine stock with no revenues

June 17 (UPI) — Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the firm reporting no revenues.

The stock split triggered a 280% share price increase on Monday, CNBC reported, and continued a 58,000% increase in its price in 2025, with a closing cost of $78 per share on the NASDAQ trading platform on Tuesday.

The stock reached a high of $81.23 during morning trading and slumped slightly to $75.47 during Tuesday’s after-hours trading.

The stock is rated as a “buy” on the TipRanks website after Regencell officials on June 2 announced the stock split to improve its liquidity and value for shareholders.